Long-term Outcomes of Faricimab in Previously Treated Neovascular Age-related Macular Degeneration

Background and Objective: The aim of this study was to evaluate long-term outcomes of intravitreal faricimab injections (IFIs) in previously treated neovascular age-related macular degeneration (nAMD). Patients and Methods: This retrospective cohort included 204 eyes from 178 patients with nAMD previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy. Clinical and imaging data were collected at baseline, after three injections, 1 year, 2 years, and final follow-up. Results: Patients were followed for 2.5 ± 0.3 years. Central subfield thickness decreased from 267.6 ± 61.0 µm to 225.8 ± 42.1 µm ( P < .001), and treatment intervals extended from 6.5 ± 2.4 to 11.5 ± 8.0 weeks ( P < .001). Intraretinal fluid declined from 44.5% to 29.5% ( P = .048) and subretinal fluid from 67.5% to 36.8% ( P < .001), while vision and pigment epithelial detachment height remained stable. Switching from faricimab to another agent provided no added benefit. Conclusion: Faricimab demonstrated sustained anatomical improvement and treatment durability over 2.5 years, with a subset of patients showing lasting benefit.